急性心肌梗死后恩格列净治疗研究
EMPACT-MI 为事件驱动、双盲、随机、安慰剂对照试验,纳入因急性心肌梗死住院且有心衰风险的患者,入院 14 天内随机给予恩格列净 10 mg 每日一次或安慰剂。共 3260 例接受恩格列净、3262 例接受安慰剂,中位随访 17.9 个月。主要终点首次心衰住院或全因死亡发生率:恩格列净组 267 例(8.2%)vs 安慰剂组 298 例(9.1%),发生率 5.9 vs 6.6 事件/100 患者年,HR 0.90(95%CI 0.76–1.06,P=0.21),未达统计学显著。心衰住院单组分 HR 0.77(95%CI 0.60–0.98),全因死亡 HR 0.96(95%CI 0.78–1.19)。不良事件与恩格列净已知安全性一致,两组相似。
要点
- 急性心梗后心衰风险增高患者,入院 14 天内启动恩格列净 10 mg 每日一次,主要终点(首次心衰住院或全因死亡)HR 0.90(95%CI 0.76–1.06,P=0.21),未显著降低。
- 恩格列净组首次心衰住院 118 例(3.6%)vs 安慰剂组 153 例(4.7%),HR 0.77(95%CI 0.60–0.98)。
- 全因死亡恩格列净组 169 例(5.2%)vs 安慰剂组 178 例(5.5%),HR 0.96(95%CI 0.78–1.19)。
- 中位随访 17.9 个月,主要终点发生率恩格列净组 5.9 vs 安慰剂组 6.6 事件/100 患者年。
- 不良事件与恩格列净已知安全性一致,两组相似。
适用人群与场景
- 因急性心肌梗死住院且有心衰风险的患者,入院 14 天内入组。
处置流程与药物剂量
- 在标准治疗基础上,入院 14 天内给予恩格列净 10 mg 每日一次或安慰剂。
研究设计与关键结果
- 事件驱动、双盲、随机、安慰剂对照试验,恩格列净组 3260 例、安慰剂组 3262 例,中位随访 17.9 个月。
- 主要终点首次心衰住院或全因死亡:恩格列净组 267 例(8.2%)vs 安慰剂组 298 例(9.1%),发生率 5.9 vs 6.6 事件/100 患者年,HR 0.90(95%CI 0.76–1.06,P=0.21)。
- 首次心衰住院:恩格列净组 118 例(3.6%)vs 安慰剂组 153 例(4.7%),HR 0.77(95%CI 0.60–0.98)。
- 全因死亡:恩格列净组 169 例(5.2%)vs 安慰剂组 178 例(5.5%),HR 0.96(95%CI 0.78–1.19)。
- 不良事件与恩格列净已知安全性一致,两组相似。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验(EMPACT-MI,NCT04509674)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:急性心梗后心衰风险增高的患者中,恩格列净治疗未较安慰剂显著降低首次心衰住院或全因死亡风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who have had acute myocardial infarction are unknown.
METHODS: In this event-driven, double-blind, randomized, placebo-controlled trial, we assigned, in a 1:1 ratio, patients who had been hospitalized for acute myocardial infarction and were at risk for heart failure to receive empagliflozin at a dose of 10 mg daily or placebo in addition to standard care within 14 days after admission. The primary end point was a composite of hospitalization for heart failure or death from any cause as assessed in a time-to-first-event analysis.
RESULTS: A total of 3260 patients were assigned to receive empagliflozin and 3262 to receive placebo. During a median follow-up of 17.9 months, a first hospitalization for heart failure or death from any cause occurred in 267 patients (8.2%) in the empagliflozin group and in 298 patients (9.1%) in the placebo group, with incidence rates of 5.9 and 6.6 events, respectively, per 100 patient-years (hazard ratio, 0.90; 95% confidence interval [CI], 0.76 to 1.06; P = 0.21). With respect to the individual components of the primary end point, a first hospitalization for heart failure occurred in 118 patients (3.6%) in the empagliflozin group and in 153 patients (4.7%) in the placebo group (hazard ratio, 0.77; 95% CI, 0.60 to 0.98), and death from any cause occurred in 169 (5.2%) and 178 (5.5%), respectively (hazard ratio, 0.96; 95% CI, 0.78 to 1.19). Adverse events were consistent with the known safety profile of empagliflozin and were similar in the two trial groups.
CONCLUSIONS: Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, NCT04509674.).
参考来源
- Butler J, Jones WS, Udell JA, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024. PMID: 38587237. doi:10.1056/NEJMoa2314051
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。